

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human MEGF9 in direct ELISAs and Western blots.
Source	Polyclonal Sheep IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived recombinant human MEGF9 Ala36-Asn514 Accession # Q9H1U4
Conjugate	Alexa Fluor 350 Excitation Wavelength: 346 nm Emission Wavelength: 442 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide
*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.	

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot	Optimal dilution of this antibody should be experimentally determined.
Immunohistochemistry	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

MEGF9 (Multiple EGF-like domains protein 9; also EGF-like protein 5) is a 63 kDa (predicted) novel transmembrane glycoprotein that shares some homology to β-chains of laminin. It is expressed by hepatocytes, cerebellar Purkinje cells, Schwann cells, keratinocytes and intestinal epithelium. MEGF9 is suggested to participate in cell motility, and its absence correlates with tumor cell migration. Mature human MEGF9 is 572 amino acids (aa) in length. It is a single span type I transmembrane protein that contains a 484 aa extracellular region (aa 31-514) plus a 68 aa C-terminal cytoplasmic domain. The extracellular region possesses a lengthy Pro-rich region (aa 55-200), followed by five EGF-like domains (aa 204-451). MEGF9 may run at approximately 160 kDa in SDS-PAGE, suggesting either heavy glycosylation or dimerization. Over aa 36-514, human MEGF9 shares 76% aa sequence identity with mouse MEGF9.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.